Stockscreener 앱 받기
0.7501
3.32%
0.0241
시간 외 거래:
.71
-0.0401
-5.35%
전일 마감가:
$0.726
열려 있는:
$0.7187
하루 거래량:
125.45K
Relative Volume:
0.07
시가총액:
$4.79M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+20.98%
1개월 성능:
-7.96%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$0.69
$0.77
1주일 범위
$0.63
$0.84
52주 변동 폭
$0.615
$1.41
Decoy Therapeutics Inc Stock (DCOY) Company Profile
명칭
Decoy Therapeutics Inc
전화
346-772-0346
주소
2450 HOLCOMBE BLVD, HOUSTON
Compare DCOY vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DCOY
Decoy Therapeutics Inc
|
0.7501 | 4.63M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Decoy Therapeutics Inc Stock (DCOY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-23 | 개시 | Ladenburg Thalmann | Buy |
| 2020-04-27 | 개시 | Ladenburg Thalmann | Buy |
Decoy Therapeutics Inc 주식(DCOY)의 최신 뉴스
Decoy Therapeutics Joins Webull Corporate Connect Service Platfo - GuruFocus
Decoy Therapeutics Joins Webull Corporate Connect Service Platform - marketscreener.com
Follow Decoy Therapeutics updates on Webull app now - Stock Titan
Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - Finviz
Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement - Finviz
Gates Foundation backs Decoy's push for rapid, low-cost antivirals - Stock Titan
Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial | DCOY Stock News - Longbridge
This MasTec Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Decoy Therapeutics (DCOY) Receives "Buy" Rating from Ladenburg T - GuruFocus
Hanish, director at Salarius, sells shares worth $17 By Investing.com - Investing.com Nigeria
DCOY Stock Price, News & Analysis - Stock Titan
DCOY Stock Price and Chart — NASDAQ:DCOY - TradingView — Track All Markets
Decoy Therapeutics Inc. (DCOY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of A Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - marketscreener.com
Decoy Therapeutics Reaches Global Access Commitment Agreement With Gates Foundation; Stock Up - Nasdaq
Decoy Therapeutics Faces Challenges Amid Market Fluctuations - StocksToTrade
Decoy Therapeutics Faces Major Headwinds Amid Financial Struggles - timothysykes.com
Decoy Therapeutics reaches global access commitment agreement to focus on development of a globally accessible, scalable peptide-conjugate manufacturing platform - marketscreener.com
Decoy Therapeutics rises as Gates Foundation backs antiviral drug access - TradingView
Decoy Therapeutics Reaches Global Access Commitment Agreement To Focus On Development Of A Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - TradingView — Track All Markets
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - PR Newswire
Salarius Pharmaceuticals shareholders re-elect directors and approve proposals at annual meeting - Investing.com Nigeria
Salarius announces planned corporate name change to Decoy Therapeutics - MSN
Salarius Pharmaceuticals Rebrands as Decoy Therapeutics on Nasdaq - The Globe and Mail
DCOY - Finviz
Salarius Pharmaceuticals changes name to Decoy Therapeutics - marketscreener.com
Salarius Pharmaceuticals to rebrand as Decoy Therapeutics, change ticker By Investing.com - Investing.com Australia
Salarius Pharmaceuticals stock soars on name change to Decoy Therapeutics By Investing.com - Investing.com South Africa
Salarius Pharmaceuticals to rebrand as Decoy Therapeutics, change ticker - Investing.com
Salarius Pharmaceuticals stock soars on name change to Decoy Therapeutics - Investing.com
Salarius Pharmaceuticals, Inc. Announces Rebranding to Decoy Therapeutics Inc. with Nasdaq Trading Under DCOY Starting January 8, 2026 - Quiver Quantitative
Salarius Pharmaceuticals Changes Corporate Name to Decoy - GlobeNewswire
Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics - The Manila Times
Salarius Pharmaceuticals faces potential Nasdaq delisting after bid price rule breach - Investing.com UK
Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting - GlobeNewswire
Salarius to change name to Decoy Therapeutics, adopt DCOY ticker - Investing.com
Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study - The Manila Times
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX” - GlobeNewswire
Salarius Pharmaceuticals clarifies continued Nasdaq listing after merger - Investing.com
Salarius Pharmaceuticals and Decoy Therapeutics Finalize Merger - citybiz
Salarius Pharmaceuticals Explorates Merger and Funding Moves - StocksToTrade
Salarius Pharmaceuticals, Inc. (SLRX) Stock: Plunges 51% After $7M Public Offering Announcement - parameter.io
Salarius Pharma Stock Jumps After-Hours As Nasdaq Compliance Clears Path For Decoy Merger — Retail Bulls Bet On Breakout - Stocktwits
Salarius Pharmaceuticals amends merger terms, adjusts preferred stock conversion - Investing.com
Salarius Pharmaceuticals Regains Nasdaq Compliance with Minimum Bid Price Requirement - Quiver Quantitative
Salarius Pharmaceuticals appoints Mark J. Rosenblum as acting CEO - Investing.com
Salarius Pharmaceuticals Appoints New Acting CEO - TipRanks
Salarius Pharmaceuticals to implement 1-for-15 reverse stock split - Investing.com
Decoding Salarius Pharmaceuticals’ Stock Movement - timothysykes.com
Salarius Pharmaceuticals granted Nasdaq extension to regain listing compliance - Investing.com
Decoy Therapeutics Inc (DCOY) 재무 분석
Decoy Therapeutics Inc (DCOY)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Decoy Therapeutics Inc 주식 (DCOY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| HANISH ARNOLD C | Director |
Dec 30 '25 |
Sale |
0.64 |
12 |
8 |
0 |
| HANISH ARNOLD C | Director |
Nov 20 '25 |
Buy |
0.75 |
5,000 |
3,740 |
5,015 |
| Rosenblum Mark J | Exec VP Finance, CFO |
Nov 20 '25 |
Buy |
0.80 |
20,000 |
16,000 |
20,177 |
1.24%
0.19%
자본화:
|
볼륨(24시간):